About Us
Kedrion Biopharma is a biopharmaceutical company that collects and fractionates blood plasma to produce and distribute worldwide plasma-derived therapies for use in treating and preventing serious diseases, disorders and conditions such as Hemophilia, Primary immunodeficiencies and Rh sensitization, which can lead to Hemolytic Disease of the Fetus and Newborn.
Kedrion was established in Italy in 2001, but the roots of the companies from which it was born stretch back several decades in the production of plasma-derived products.
In 2022, Kedrion joined forces with BPL (Bio Products Laboratory), a UK-based company with over 60 years of experience in the supply of high-quality plasma-derived medicines to treat rare diseases.
Kedrion’s acquisition of Prometic, and of its first-ever therapy for Congenital Plasminogen Deficiency, in 2021, confirmed our commitment to fighting rare, or even extremely rare, diseases.
Kedrion around the world
Kedrion is a global player in plasma derivatives and rare disease medicines employing more than 4,800 people worldwide.
We have 7 production plants over 5 countries in Europe and North America, with BPL’s site at Elstree, UK, being the latest addition to our manufacturing network.
We operate plasma collection centers in the United States and Czech Republic, and we distribute our products in over 100 countries around the world. With these figures, we are the world’s 5th top player in the field of plasma-derived products.
Kedrion places a high value on the welfare of those who benefit from its products, as well as of the communities and individuals with whom it works and collaborates.
We look forward to continued expansion and the wider sharing of our experience, know-how and technology to bring healthier and less restricted lives to people suffering from rare disorders.
Vision
Everyone has the right to life, liberty and security of person*
Sometimes, natural, accidental or social causes obstruct the natural right to life, liberty and personal security. Because of the special nature of its products, Kedrion supports people, communities and institutions in reducing or removing those obstacles that prevent people enjoying such rights. Kedrion helps turn the natural rights (life, liberty, security) into the social right to live in the best possible conditions.
For this reason, it collects and converts, makes active and usable that vital energy that is generated and regenerated, preserved and carried through blood; so that it can be transferred from one human being to the next, and anyone can enjoy one’s fundamental rights.
*Universal Declaration of Human Rights, art. 3.
Our mission
Kedrion produces and distributes human plasma-derived medicinal products used to treat and prevent rare and debilitating diseases and disorders. Kedrion works to maintain excellent industry standards and aspires to ongoing improvement, in order to retain a leading position in Italy and to increase its share of the international market. It works to strengthen its role as the accredited partner of the medical, scientific and institutional communities.
Kedrion’s ambition is to enhance its worldwide role as a strategic partner of the national health systems of those countries which aim to become self-sufficient in the availability of plasma-derived products, also via technology transfer.
Kedrion produces wealth for investors, employees and for the local community, consistently with its own vision and values: responsibility, transparency, confidence in and respect for people.
OUR COMMITMENTS
SOCIAL RESPONSIBILITY
To act as responsible global citizens respecting all the communities with whom and for whom we work.
TRANSPARENCY
To make accurate and comprehensive information available to all stakeholders.
QUALITY AND SAFETY
To demonstrate care and respect for our clients, our collaborators and our employees by continuous emphasis on the quality and safety of all our products and processes.
